Decreased Serotonin 2A Receptor Densities in Neuroleptic-Naive Patients With Schizophrenia: A PET Study Using [18F]Setoperone

OBJECTIVE: The authors compared serotonin receptor binding in patients with schizophrenia and healthy comparison subjects.METHOD: They used positron emission tomography with [18F]setoperone to examine six patients with schizophrenia who had never been given neuroleptics and seven age-matched subject...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of psychiatry 2000-06, Vol.157 (6), p.1016-1018
Main Authors: Ngan, Elton T.C., Yatham, Lakshmi N., Ruth, Thomas J., Liddle, Peter F.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antipsychotic Agents - therapeutic use
Biochemistry
Brain - diagnostic imaging
Brain - metabolism
Female
Fluorine Radioisotopes
Frontal Lobe - diagnostic imaging
Frontal Lobe - metabolism
Humans
Male
Psychiatry
Pyrimidinones
Radionuclide Imaging
Receptor, Serotonin, 5-HT2A
Receptors, Serotonin - metabolism
Schizophrenia
Schizophrenia - diagnostic imaging
Schizophrenia - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: The authors compared serotonin receptor binding in patients with schizophrenia and healthy comparison subjects.METHOD: They used positron emission tomography with [18F]setoperone to examine six patients with schizophrenia who had never been given neuroleptics and seven age-matched subjects who did not have schizophrenia.RESULTS: A nondirected voxel-based analysis of the subjects' entire search volume found that serotonin 2A binding potential in the frontal cortex index was significantly smaller (by 16.3%) in patients with schizophrenia than in healthy subjects.CONCLUSIONS: The authors conclude that the decrease in serotonin receptor densities previously reported in postmortem studies of subjects with schizophrenia are present at the onset of the illness, before exposure to neuroleptics.
ISSN:0002-953X
1535-7228
DOI:10.1176/appi.ajp.157.6.1016